Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Toshio Asayama, MD, Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Yasuko Hamada, MD, Namiko Okuyama, MD, Asaka Onodera, MDPhD, Akiko Yamada, MD, Keiichi Moriya, MD PhD, Norio Yokose, MD PhD, Koiti Inokuchi, PhD MD

Blood (2015) 126 (23): 4117.

https://doi.org/10.1182/blood.V126.23.4117.4117

Published: 2015

Journal Articles

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Yasuko Hamada, MD, Mariko Ishibashi, PhD, Toshio Asayama, MD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Hideya Hyodo, MD, PhD, Takehito Igarashi, MD, PhD, Hiroyuki Onose, MD, PhD, Norio Yokose, MD, PhD, Sakae Tanosaki, MD, PhD, Kazuo Shimizu, MD, PhD, Hideto Tamura, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 4320.

https://doi.org/10.1182/blood.V122.21.4320.4320

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only